A Phase 1 interventional study of Dolutegravir and Lamivudine in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-21.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to compare the bioequivalence of two experimental fixed dose combination (FDC) tablets versus single entity products of dolutegravir (DTG) and lamivudine (3TC) in healthy adult subjects. The study will be carried out in two parts. Part 1 of the study will be open label, up to 3 periods design with a wash out period of at least 7 days between treatment periods. Subjects will be randomized to receive either single entities or formulation 1 FDC of DTG and 3TC in a crossover manner in first 2 periods. The first 16 subjects who complete the first two treatment periods and consent to continue will receive a single dose of FDC formulation 1 tablet administered with a high fat meal for a third treatment period. In Part 2 of the study, subjects will be randomized to receive either single entities or formulation 2 FDC of DTG and 3TC in a crossover manner in first 2 periods. Similarly the first 16 subjects will then receive FDC formulation 2 tablets with high fat meal in treatment period 3. Subjects will have a follow-up visit within 7-14 days after the last dose of study drug. Approximately 76 healthy subjects will be included in Part 1 of the study and if Part 2 of the study is conducted, another 76 healthy subjects will be included. The total duration will be approximately 11 weeks.
2,096 studies on the registry are indexed under Infections; 364 are open to participants now.
This study's enrollment of 154 is above the median of 113 across 1,304 interventional studies indexed under Infections.
Browse Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible subjects will be randomized in sequence A/B and will receive A: DTG 50 milligram (mg) and 3TC 300 mg single entities in Period 1, B: DTG 3TC FDC formulation 1 tablet in Period 2.
Drug: Dolutegravir · Drug: Lamivudine · Drug: Dolutegravir + Lamivudine FDC Formulation 1
Eligible subjects will be randomized in sequence B/A and will receive B: DTG 3TC FDC formulation 1 tablet in Period 1 and A: DTG 50 mg and 3TC 300 mg single entities in Period 2.
Drug: Dolutegravir · Drug: Lamivudine · Drug: Dolutegravir + Lamivudine FDC Formulation 1
Eligible subjects will be administered single dose of DTG 3TC FDC formulation 1 tablet with high fat meal in Period 3 to study the effect of food on tablet.
Drug: Dolutegravir + Lamivudine FDC Formulation 1
Eligible subjects will be randomized in sequence A/B and will receive A: DTG 50 mg and 3TC 300 mg single entities in Period 1 and C: DTG 3TC FDC formulation 2 tablet in Period 2.
Drug: Dolutegravir · Drug: Lamivudine · Drug: Dolutegravir + Lamivudine FDC Formulation 2
Eligible subjects will be randomized in sequence C/A and will receive C: DTG 3TC FDC formulation 2 tablet in Period 1 and A: DTG 50 milligram (mg) and 3TC 300 mg single entities in Period 2.
Drug: Dolutegravir · Drug: Lamivudine · Drug: Dolutegravir + Lamivudine FDC Formulation 2
Eligible subjects will be administered single dose of DTG 3TC FDC formulation 2 tablet with high fat meal in Period 3 to study the effect of food on tablet.
Drug: Dolutegravir + Lamivudine FDC Formulation 2
Single dose of DTG 50 mg tablet along with 3TC (EPIVIR) tablet will be given to randomized subjects in parts 1 and 2 with 240 mL of room temperature water. DTG will be a white, film coated, round tablet engraved with SV 572 on one side and 50 on the other side.
Single dose 3TC (commercial name: EPIVIR) 300 mg tablet along with DTG tablet will be given to randomized subjects in parts 1 and 2 with 240 mL of room temperature water.\<br\>3TC will be gray, diamond shaped tablet, engraved "GX EJ7" on one side and plain on the other side.
Single dose of DTG 50 mg combined with 3TC 300 mg in a FDC formulation 1 tablet will be administered to randomized subjects in treatment periods 1 and 2 (under fasted state) of Part 1 and the first 16 subjects in treatment period 3 (under fed) of Part 1 with 240 mL of room temperature water. \<br\>FDC formulation 1 tablets will be oval, biconvex, white, film coated tablet engraved 'SV H7I' on one face.
Single dose of DTG 50 mg combined with 3TC 300 mg in a FDC formulation 2 tablet will be administered to randomized subjects in treatment periods 1 and 2 (under fasted state) and the first 16 subjects in treatment period 3 (under fed) of Part 2 with 240 mL of room temperature water. \<br\>FDC formulation 2 tablets will be oval, biconvex, white, film coated tablet engraved 'SV 13N' on one face.
Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity [AUC (0-Inf)] of Plasma DTG and 3TC in the Fasted State: Part 1
Blood samples were collected at indicated time points to study the pharmacokinetic (PK) profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
AUC (0-Inf) of Plasma DTG and 3TC in the Fasted State: Part 2
Blood samples were collected at given time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted conditions in Periods 1 and 2 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Area Under the Concentration-time Curve From Time 0 to the Last Quantifiable Time Point (AUC[0-t]) of Plasma DTG and 3TC in the Fasted State: Part 1
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
AUC(0-t) of Plasma DTG and 3TC in the Fasted State: Part 2
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Maximum Observed Concentration (Cmax) of Plasma DTG and 3TC in the Fasted State: Part 1
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Cmax of Plasma DTG and 3TC in the Fasted State: Part 2
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Absorption Lag Time (Tlag) of DTG and 3TC in Fasted State: Part 1
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Tlag of DTG and 3TC in Fasted State: Part 2
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Time to Reach Maximum Plasma Concentration (Tmax) of DTG and 3TC in the Fasted State: Part 1
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Tmax of DTG and 3TC in the Fasted State: Part 2
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Time of the Last Quantifiable Concentration (Tlast) of DTG and 3TC in the Fasted State: Part 1
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Tlast of DTG and 3TC in the Fasted State: Part 2
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Time to Reach Half the Maximum Plasma Concentration (t1/2) of DTG and 3TC in the Fasted State: Part 1
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
t1/2 of DTG and 3TC in the Fasted State: Part 2
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Apparent Elimination Rate Constant (Lambda z) of DTG and 3TC in the Fasted State: Part 1
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Lambda z of DTG and 3TC in in the Fasted State: Part 2
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Percentage of Extrapolated AUC (0 to Inf) of DTG and 3TC in the Fasted State: Part 1
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Percentage of Extrapolated AUC(0 to Inf) of DTG and 3TC in the Fasted State: Part 2
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
AUC of 0 to 24 Hours (AUC[0-24]) of DTG and 3TC in the Fasted State: Part 1
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
AUC(0-24) of DTG and 3TC in the Fasted State: Part 2
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Apparent Oral Clearance (CL/F) of DTG and 3TC in the Fasted State: Part 1
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
CL/F of DTG and 3TC in the Fasted State: Part 2
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Apparent Oral Volume of Distribution (Vz/F) of DTG and 3TC in the Fasted State: Part 1
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Vz/F of DTG and 3TC in the Fasted State: Part 2
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Concentration at 24 Hours Post-dose (C24) of DTG and 3TC in the Fasted State: Part 1
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
C24 of DTG and 3TC in the Fasted State: Part 2
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Last Quantifiable Concentration (Clast) of DTG and 3TC in the Fasted State: Part 1
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Clast of DTG and 3TC in the Fasted State: Part 2
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
AUC (0-Inf) of Plasma DTG and 3TC in the Fed State: Part 1
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
AUC (0-Inf) of Plasma DTG and 3TC in the Fed State: Part 2
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
AUC (0-t) of Plasma DTG and 3TC in the Fed State: Part 1
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
AUC (0-t) of Plasma DTG and 3TC in the Fed State: Part 2
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Cmax of Plasma DTG and 3TC in the Fed State: Part 1
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Cmax of Plasma DTG and 3TC in the Fed State: Part 2
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Tlag of DTG and 3TC in Fed State: Part 1
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Tlag of DTG and 3TC in Fed State: Part 2
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Tmax of DTG and 3TC in the Fed State: Part 1
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Tmax of DTG and 3TC in the Fed State: Part 2
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
T1/2 of DTG and 3TC in the Fed State: Part 1
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
T1/2 of DTG and 3TC in the Fed State: Part 2
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Lambda z of DTG and 3TC in in the Fed State: Part 1
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Lambda z of DTG and 3TC in in the Fed State: Part 2
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Clast of DTG and 3TC in in the Fed State: Part 1
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Clast of DTG and 3TC in in the Fed State: Part 2
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Percentage of Extrapolated AUC (0-inf) in the Fed State: Part 1
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Percentage of Extrapolated AUC (0-inf) in the Fed State: Part 2
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
AUC(0-24) of DTG and 3TC in the Fed State: Part 1
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
AUC(0-24) of DTG and 3TC in the Fed State: Part 2
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
CL/F of DTG and 3TC in the Fed State: Part 1
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
CL/F of DTG and 3TC in the Fed State: Part 2
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Tlast of DTG and 3TC in the Fed State: Part 1
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Tlast of DTG and 3TC in the Fed State: Part 2
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Vz/F of DTG and 3TC in the Fed State: Part 1
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Vz/F of DTG and 3TC in the Fed State: Part 2
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
C24 of DTG and 3TC in the Fed State: Part 1
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
C24 of DTG and 3TC in the Fed State: Part 2
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): Part 1 and 2
SBP and DBP were measured in the supine or semi-supine position after 5 minutes rest. The Baseline value was considered to be the participant's last available assessment prior to time of the first dose. Change from Baseline was defined as post dose visit value minus Baseline value. Data for SBP and DBP for Part 1 and 2 is presented.
Time frame: Up to Day 31 in Part 1 and Part 2
Change From Baseline in Heart Rate (HR): Part 1 and 2
HR was measured in the supine or semi-supine position after 5 minutes rest. The Baseline value was considered to be the participant's last available assessment prior to time of the first dose. Change from Baseline was defined as post dose visit value minus Baseline value. Data for HR for Part 1 and 2 is presented.
Time frame: Up to Day 31 in Part 1 and Part 2
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs): Part 1 and 2
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinaemia were categorized as SAE. Participants having any AE or SAE are presented.
Time frame: Up to Week 11
The study was conducted in 2 parts (Part 1 and Part 2) at a single center in the United States from 27-March-2017 to 18-August-2017 and 154 participants (78 in Part 1 and 76 in Part 2) were randomized. First 16 participants completing the first 2 dosing periods, returned for a 3rd treatment period and received single dose of FDC with high fat meal
| Milestone | Part 1:DTG+EPIVIR/DTG+3TC Monolayer/DTG+3TC Monolayer-fed | Part 1:DTG+3TC Monolayer/DTG+EPIVIR/DTG+3TC Monolayer-fed | Part 2:DTG+EPIVIR/DTG+3TC Bilayer/DTG+3TC Bilayer-fed | Part 2:DTG+3TC Bilayer/DTG+EPIVIR /DTG+3TC Bilayer-fed |
|---|---|---|---|---|
| Started | 39 | 39 | 38 | 38 |
| Completed | 39 | 38 | 38 | 38 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Milestone | Part 1:DTG+EPIVIR/DTG+3TC Monolayer/DTG+3TC Monolayer-fed | Part 1:DTG+3TC Monolayer/DTG+EPIVIR/DTG+3TC Monolayer-fed | Part 2:DTG+EPIVIR/DTG+3TC Bilayer/DTG+3TC Bilayer-fed | Part 2:DTG+3TC Bilayer/DTG+EPIVIR /DTG+3TC Bilayer-fed |
|---|---|---|---|---|
| Started | 39 | 38 | 38 | 38 |
| Completed | 37 | 36 | 37 | 37 |
| Not completed | 2 | 2 | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 |
| Milestone | Part 1:DTG+EPIVIR/DTG+3TC Monolayer/DTG+3TC Monolayer-fed | Part 1:DTG+3TC Monolayer/DTG+EPIVIR/DTG+3TC Monolayer-fed | Part 2:DTG+EPIVIR/DTG+3TC Bilayer/DTG+3TC Bilayer-fed | Part 2:DTG+3TC Bilayer/DTG+EPIVIR /DTG+3TC Bilayer-fed |
|---|---|---|---|---|
| Started | 37 | 36 | 37 | 37 |
| Completed | 37 | 36 | 37 | 37 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Part 1:DTG+EPIVIR/DTG+3TC Monolayer/DTG+3TC Monolayer-fed | Part 1:DTG+3TC Monolayer/DTG+EPIVIR/DTG+3TC Monolayer-fed | Part 2:DTG+EPIVIR/DTG+3TC Bilayer/DTG+3TC Bilayer-fed | Part 2:DTG+3TC Bilayer/DTG+EPIVIR /DTG+3TC Bilayer-fed |
|---|---|---|---|---|
| Started | 9 | 7 | 7 | 9 |
| Completed | 9 | 7 | 7 | 9 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Part 1:DTG+EPIVIR/DTG+3TC Monolayer/DTG+3TC Monolayer-fed | Part 1:DTG+3TC Monolayer/DTG+EPIVIR/DTG+3TC Monolayer-fed | Part 2:DTG+EPIVIR/DTG+3TC Bilayer/DTG+3TC Bilayer-fed | Part 2:DTG+3TC Bilayer/DTG+EPIVIR /DTG+3TC Bilayer-fed |
|---|---|---|---|---|
| Started | 9 | 7 | 7 | 9 |
| Completed | 9 | 7 | 7 | 9 |
| Not completed | 0 | 0 | 0 | 0 |
Blood samples were collected at indicated time points to study the pharmacokinetic (PK) profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
| Hour*micrograms per milliliter | A: DTG 50 mg + EPIVIR 300 mg | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC |
|---|---|---|
| DTG | 43.1456 ± 39.29 | 54.8793 ± 31.60 |
| 3TC | 12.3337 ± 19.88 | 12.7603 ± 19.77 |
Blood samples were collected at given time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted conditions in Periods 1 and 2 of Part 2.
| Hours*micrograms per milliliter | A: DTG 50 mg + EPIVIR 300 mg | C: DTG 50 mg/ 3TC 300 mg Bilayer FDC |
|---|---|---|
| DTG, n= 74,74 | 47.2391 ± 40.29 | 54.5594 ± 32.12 |
| 3TC, n= 73,74 | 12.7713 ± 18.63 | 13.5624 ± 17.94 |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
| Hours*micrograms per milliliter | A: DTG 50 mg + EPIVIR 300 mg | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC |
|---|---|---|
| DTG | 41.4207 ± 39.36 | 52.8754 ± 31.16 |
| 3TC | 12.1571 ± 20.19 | 12.6147 ± 19.75 |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.
| Hour*microgram/milliliter | A: DTG 50 mg + EPIVIR 300 mg | C: DTG 50 mg/ 3TC 300 mg Bilayer FDC |
|---|---|---|
| DTG | 45.2043 ± 39.57 | 52.3372 ± 31.46 |
| 3TC | 12.4790 ± 19.19 | 13.3552 ± 18.10 |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
| Micrograms per milliliter | A: DTG 50 mg + EPIVIR 300 mg | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC |
|---|---|---|
| DTG | 2.4065 ± 38.95 | 3.0817 ± 31.86 |
| 3TC | 2.6650 ± 29.04 | 3.1885 ± 28.07 |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.
| Micrograms per milliliter | A: DTG 50 mg + EPIVIR 300 mg | B: DTG 50 mg/ 3TC 300 mg Bilayer FDC |
|---|---|---|
| DTG | 2.5531 ± 36.38 | 2.9132 ± 30.55 |
| 3TC | 2.4428 ± 28.25 | 3.2185 ± 29.30 |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
| Hour | A: DTG 50 mg + EPIVIR 300 mg | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC |
|---|---|---|
| DTG | 0.0000 (0.0000 to 0.756) | 0.0000 (0.0000 to 0.261) |
| 3TC | 0.0000 (0.0000 to 0.252) | 0.0000 (0.0000 to 0.261) |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.
| Hour | A: DTG 50 mg + EPIVIR 300 mg | C: DTG 50 mg/ 3TC 300 mg Bilayer FDC |
|---|---|---|
| DTG | 0.0000 (0.0000 to 0.261) | 0.0000 (0.0000 to 0.266) |
| 3TC | 0.0000 (0.0000 to 0.0000) | 0.0000 (0.0000 to 0.252) |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
| Hour | A: DTG 50 mg + EPIVIR 300 mg | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC |
|---|---|---|
| DTG | 2.0072 (0.500 to 8.009) | 2.0017 (0.500 to 5.012) |
| 3TC | 1.0047 (0.500 to 4.005) | 1.0008 (0.500 to 3.500) |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2
| Hour | A: DTG 50 mg + EPIVIR 300 mg | C: DTG 50 mg/ 3TC 300 mg Bilayer FDC |
|---|---|---|
| DTG | 2.5008 (0.500 to 5.011) | 2.5004 (0.500 to 6.001) |
| 3TC | 1.0063 (0.500 to 4.002) | 1.0011 (0.500 to 3.501) |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
| Hour | A: DTG 50 mg + EPIVIR 300 mg | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC |
|---|---|---|
| DTG | 72.0031 (48.000 to 74.636) | 71.9303 (48.003 to 76.236) |
| 3TC | 71.9289 (47.673 to 74.636) | 71.9303 (70.790 to 76.236) |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2
| Hour | A: DTG 50 mg + EPIVIR 300 mg | C: DTG 50 mg/ 3TC 300 mg Bilayer FDC |
|---|---|---|
| DTG | 71.6813 (48.006 to 75.301) | 71.8243 (71.005 to 72.632) |
| 3TC | 71.7138 (48.000 to 75.301) | 71.8153 (48.007 to 72.632) |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
| Hour | A: DTG 50 mg + EPIVIR 300 mg | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC |
|---|---|---|
| DTG | 14.6917 (10.575 to 21.375) | 14.7557 (10.461 to 21.392) |
| 3TC | 17.0395 (8.281 to 34.542) | 17.3436 (12.436 to 34.675) |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2
| Hour | A: DTG 50 mg + EPIVIR 300 mg | C: DTG 50 mg/ 3TC 300 mg Bilayer FDC |
|---|---|---|
| DTG, n= 74,74 | 15.1538 (9.711 to 21.966) | 14.7893 (9.815 to 21.486) |
| 3TC, n= 73,74 | 17.8421 (10.195 to 47.171) | 18.1071 (7.367 to 48.613) |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
| Per hour | A: DTG 50 mg + EPIVIR 300 mg | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC |
|---|---|---|
| DTG | 0.0472 (0.032 to 0.066) | 0.0470 (0.032 to 0.066) |
| 3TC | 0.0407 (0.020 to 0.084) | 0.0400 (0.020 to 0.056) |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.
| Per hour | A: DTG 50 mg + EPIVIR 300 mg | C: DTG 50 mg/ 3TC 300 mg Bilayer FDC |
|---|---|---|
| DTG, n=74,74 | 0.0457 (0.032 to 0.071) | 0.0469 (0.032 to 0.071) |
| 3TC, n= 73,74 | 0.0388 (0.015 to 0.068) | 0.0383 (0.014 to 0.094) |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
| Percentage of AUC | A: DTG 50 mg + EPIVIR 300 mg | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC |
|---|---|---|
| DTG | 3.4967 (1.015 to 15.084) | 3.2582 (0.908 to 9.967) |
| 3TC | 1.0287 (0.343 to 7.305) | 0.9052 (0.428 to 5.334) |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.
| Percentage of AUC | A: DTG 50 mg + EPIVIR 300 mg | C: DTG 50 mg/ 3TC 300 mg Bilayer FDC |
|---|---|---|
| DTG, n= 74,74 | 3.8923 (0.932 to 10.512) | 3.5773 (0.659 to 9.570) |
| 3TC, n= 73,74 | 1.2518 (0.344 to 6.409) | 1.1432 (0.394 to 7.867) |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
| Hours*microgram per milliliter | A: DTG 50 mg + EPIVIR 300 mg | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC |
|---|---|---|
| DTG | 29.4257 ± 38.40 | 37.6112 ± 30.28 |
| 3TC | 11.3960 ± 20.92 | 11.9418 ± 20.09 |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.
| Hours*microgram per milliliter | A: DTG 50 mg + EPIVIR 300 mg | C: DTG 50 mg/ 3TC 300 mg Bilayer FDC |
|---|---|---|
| DTG | 31.5664 ± 37.73 | 36.6126 ± 30.93 |
| 3TC | 11.6419 ± 20.23 | 12.5810 ± 18.50 |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
| Liters per hour | A: DTG 50 mg + EPIVIR 300 mg | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC |
|---|---|---|
| DTG | 1.1589 ± 39.29 | 0.9111 ± 31.60 |
| 3TC | 24.3236 ± 19.88 | 23.5104 ± 19.77 |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.
| Liters per hour | A: DTG 50 mg + EPIVIR 300 mg | C: DTG 50 mg/ 3TC 300 mg Bilayer FDC |
|---|---|---|
| DTG, n= 74, 74 | 1.0584 ± 40.29 | 0.9164 ± 32.12 |
| 3TC, n= 73, 74 | 23.4901 ± 18.63 | 22.1200 ± 17.94 |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
| Liters | A: DTG 50 mg + EPIVIR 300 mg | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC |
|---|---|---|
| DTG | 24.6254 ± 37.80 | 19.3399 ± 30.05 |
| 3TC | 616.7365 ± 34.52 | 598.8651 ± 29.07 |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.
| Liters | A: DTG 50 mg + EPIVIR 300 mg | C: DTG 50 mg/ 3TC 300 mg Bilayer FDC |
|---|---|---|
| DTG, n= 74, 74 | 23.1159 ± 37.18 | 19.8124 ± 32.73 |
| 3TC, n= 73, 74 | 650.7952 ± 35.55 | 599.5525 ± 34.28 |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
| Micrograms per milliliter | A: DTG 50 mg + EPIVIR 300 mg | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC |
|---|---|---|
| DTG | 0.6373 ± 40.18 | 0.8059 ± 32.77 |
| 3TC | 0.0331 ± 32.13 | 0.0318 ± 31.81 |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.
| Micrograms per milliliter | A: DTG 50 mg + EPIVIR 300 mg | C: DTG 50 mg/ 3TC 300 mg Bilayer FDC |
|---|---|---|
| DTG | 0.7065 ± 41.48 | 0.8071 ± 33.83 |
| 3TC | 0.0366 ± 30.39 | 0.0350 ± 31.19 |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of monolayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 1.
| Micrograms per milliliter | A: DTG 50 mg + EPIVIR 300 mg | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC |
|---|---|---|
| DTG | 0.0702 ± 58.85 | 0.0832 ± 56.42 |
| 3TC | 0.0056 ± 43.03 | 0.0050 ± 37.58 |
Blood samples were collected at indicated time points to study the PK profile of DTG and 3TC when administered as FDC tablet compared to co-administration of separate tablet formulations of DTG and 3TC in fasted state. The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. PK parameters of bilayer FDC tablet formulation of DTG and 3TC was evaluated under fasted condition in Periods 1 and 2 of Part 2.
| Micrograms per milliliter | A: DTG 50 mg + EPIVIR 300 mg | C: DTG 50 mg/ 3TC 300 mg Bilayer FDC |
|---|---|---|
| DTG | 0.0800 ± 66.94 | 0.0862 ± 65.26 |
| 3TC | 0.0069 ± 47.83 | 0.0062 ± 41.60 |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
| Hours*microgram per milliliter | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC | Bfed: DTG 50 mg/3TC 300 mg Monolayer FDC Fed |
|---|---|---|
| DTG | 62.3435 ± 32.34 | 71.9777 ± 19.99 |
| 3TC | 13.4357 ± 21.02 | 12.8668 ± 18.50 |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
| Hours*microgram per milliliter | C: DTG 50 mg and 3TC 300 mg Bilayer FDC | Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed |
|---|---|---|
| DTG | 57.6561 ± 35.93 | 76.4283 ± 22.36 |
| 3TC | 14.6420 ± 18.50 | 13.3443 ± 20.34 |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
| Hour*microgram per milliliter | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC | Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed |
|---|---|---|
| DTG | 60.3212 ± 31.78 | 69.2560 ± 18.92 |
| 3TC | 13.2818 ± 20.90 | 12.6491 ± 18.63 |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
| Hour*microgram per milliliter | C: DTG 50 mg and 3TC 300 mg Bilayer FDC | Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed |
|---|---|---|
| DTG | 55.2176 ± 35.33 | 72.7545 ± 20.22 |
| 3TC | 14.4706 ± 18.72 | 13.0923 ± 20.57 |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
| Micrograms per milliliter | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC | Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed |
|---|---|---|
| DTG | 3.5068 ± 30.27 | 3.7900 ± 20.97 |
| 3TC | 3.5413 ± 27.14 | 2.5132 ± 18.74 |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
| Micrograms per milliliter | C: DTG 50 mg and 3TC 300 mg Bilayer FDC | Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed |
|---|---|---|
| DTG | 3.1015 ± 35.62 | 3.7516 ± 21.31 |
| 3TC | 3.5824 ± 35.18 | 2.4453 ± 33.88 |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
| Hour | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC | Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed |
|---|---|---|
| DTG | 0.0000 (0.0000 to 0.251) | 0.2522 (0.0000 to 1.000) |
| 3TC | 0.0000 (0.0000 to 0.251) | 0.0000 (0.0000 to 0.255) |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
| Hour | C: DTG 50 mg and 3TC 300 mg Bilayer FDC | Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed |
|---|---|---|
| DTG | 0.0000 (0.0000 to 0.258) | 0.1253 (0.0000 to 0.751) |
| 3TC | 0.0000 (0.0000 to 0.252) | 0.0000 (0.0000 to 0.257) |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
| Hour | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC | Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed |
|---|---|---|
| DTG | 1.5013 (0.503 to 5.002) | 5.0006 (2.001 to 12.009) |
| 3TC | 1.0001 (0.500 to 2.001) | 3.5003 (1.011 to 5.006) |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
| Hour | C: DTG 50 mg and 3TC 300 mg Bilayer FDC | Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed |
|---|---|---|
| DTG | 1.5007 (0.751 to 3.001) | 5.0019 (1.011 to 8.004) |
| 3TC | 1.0003 (0.503 to 2.506) | 2.7508 (1.001 to 6.001) |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
| Hour | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC | Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed |
|---|---|---|
| DTG | 14.5843 (12.077 to 16.806) | 14.5816 (10.889 to 17.259) |
| 3TC | 18.3614 (12.509 to 30.759) | 19.8579 (9.977 to 34.144) |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
| Hour | C: DTG 50 mg and 3TC 300 mg Bilayer FDC | Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed |
|---|---|---|
| DTG | 14.9828 (11.355 to 20.563) | 15.1718 (12.193 to 19.945) |
| 3TC | 17.2250 (13.259 to 37.099) | 19.7311 (13.384 to 27.781) |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
| Per hour | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC | Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed |
|---|---|---|
| DTG | 0.0475 (0.041 to 0.057) | 0.0475 (0.040 to 0.064) |
| 3TC | 0.0378 (0.023 to 0.055) | 0.0349 (0.020 to 0.069) |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
| Per hour | C: DTG 50 mg and 3TC 300 mg Bilayer FDC | Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed |
|---|---|---|
| DTG | 0.0463 (0.034 to 0.061) | 0.0457 (0.035 to 0.057) |
| 3TC | 0.0403 (0.019 to 0.052) | 0.0351 (0.025 to 0.052) |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
| Micrograms per milliliter | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC | Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed |
|---|---|---|
| DTG | 0.1060 (0.035 to 0.180) | 0.1190 (0.043 to 0.243) |
| 3TC | 0.0048 (0.003 to 0.014) | 0.0066 (0.004 to 0.016) |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
| Micrograms per milliliter | C: DTG 50 mg and 3TC 300 mg Bilayer FDC | Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed |
|---|---|---|
| DTG | 0.0975 (0.031 to 0.240) | 0.1310 (0.051 to 0.363) |
| 3TC | 0.0059 (0.003 to 0.011) | 0.0091 (0.003 to 0.015) |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
| Percentage of AUC | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC | Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed |
|---|---|---|
| DTG | 3.3305 (1.490 to 4.845) | 3.8870 (1.094 to 6.134) |
| 3TC | 0.8856 (0.561 to 3.510) | 1.4830 (0.788 to 4.324) |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
| Percentage of AUC | C: DTG 50 mg and 3TC 300 mg Bilayer FDC | Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed |
|---|---|---|
| DTG | 3.6835 (1.069 to 8.601) | 3.8790 (1.561 to 9.126) |
| 3TC | 1.0443 (0.467 to 3.859) | 1.7467 (0.567 to 3.642) |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
| Hour*microgram per milliliter | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC | Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed |
|---|---|---|
| DTG | 43.1879 ± 29.88 | 46.8555 ± 16.95 |
| 3TC | 12.6113 ± 21.25 | 11.8076 ± 18.71 |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
| Hour*microgram per milliliter | C: DTG 50 mg and 3TC 300 mg Bilayer FDC | Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed |
|---|---|---|
| DTG | 38.6325 ± 34.53 | 48.2012 ± 15.53 |
| 3TC | 13.7012 ± 19.24 | 12.1065 ± 21.09 |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
| Liters per hour | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC | Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed |
|---|---|---|
| DTG | 0.8020 ± 32.34 | 0.6947 ± 19.99 |
| 3TC | 22.3285 ± 21.02 | 23.3159 ± 18.50 |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
| Liters per hour | C: DTG 50 mg and 3TC 300 mg Bilayer FDC | Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed |
|---|---|---|
| DTG | 0.8672 ± 35.93 | 0.6542 ± 22.36 |
| 3TC | 20.4890 ± 18.50 | 22.4815 ± 20.34 |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
| Hours | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC | Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed |
|---|---|---|
| DTG | 71.8265 (71.124 to 72.301) | 71.9758 (71.330 to 72.869) |
| 3TC | 71.8265 (71.124 to 72.301) | 71.9758 (71.330 to 72.869) |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
| Hours | C: DTG 50 mg and 3TC 300 mg Bilayer FDC | Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed |
|---|---|---|
| DTG | 72.0292 (71.446 to 72.269) | 71.8711 (71.080 to 72.381) |
| 3TC | 72.0292 (71.446 to 72.269) | 71.8711 (71.080 to 72.381) |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
| Liters | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC | Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed |
|---|---|---|
| DTG | 16.7520 ± 28.45 | 14.4964 ± 15.87 |
| 3TC | 593.2054 ± 29.23 | 643.0977 ± 41.08 |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
| Liters | C: DTG 50 mg and 3TC 300 mg Bilayer FDC | Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed |
|---|---|---|
| DTG | 19.0954 ± 36.45 | 14.6215 ± 11.63 |
| 3TC | 535.8125 ± 35.63 | 641.3744 ± 32.10 |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC monolayer FDC tablet formulations was assessed in Period 3 of Part 1.
| Micrograms per milliliter | B: DTG 50 mg/ 3TC 300 mg Monolayer FDC | Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed |
|---|---|---|
| DTG | 0.9216 ± 36.08 | 1.1916 ± 25.03 |
| 3TC | 0.0304 ± 33.07 | 0.0366 ± 35.90 |
Blood samples for PK analysis of DTG and 3TC were collected at given time points to study the PK profile of DTG and 3TC FDC tablet(s). The 4-hour post-dose sample was drawn prior to the participant's first post-dose meal. At each time point, 2 mL of blood was collected. The effect of food on DTG and 3TC bilayer FDC tablet formulations was assessed in Period 3 of Part 2.
| Micrograms per milliliter | C: DTG 50 mg and 3TC 300 mg Bilayer FDC | Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed |
|---|---|---|
| DTG | 0.8355 ± 38.46 | 1.2273 ± 25.73 |
| 3TC | 0.0350 ± 39.91 | 0.0417 ± 38.62 |
SBP and DBP were measured in the supine or semi-supine position after 5 minutes rest. The Baseline value was considered to be the participant's last available assessment prior to time of the first dose. Change from Baseline was defined as post dose visit value minus Baseline value. Data for SBP and DBP for Part 1 and 2 is presented.
| Millimeters of mercury | Part 1- A: DTG 50 mg + EPIVIR 300 mg | Part 1- B: DTG 50 mg/ 3TC 300 mg Monolayer FDC | Part 1-Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed | Part 2- A: DTG 50 mg + EPIVIR 300 mg | Part 2-C: DTG 50 mg and 3TC 300 mg Bilayer FDC | Part 2-Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed |
|---|---|---|---|---|---|---|
| DBP,4 hour,n=75,76,16,75,75,16 | 0.1 ± 5.85 | 0.2 ± 5.24 | -2.1 ± 4.19 | -0.5 ± 4.09 | -0.3 ± 5.71 | 0.0 ± 4.86 |
| DBP,Day 2,n=74,75,16,75,75,16 | -0.3 ± 5.53 | -0.9 ± 6.14 | 0.4 ± 5.32 | -1.7 ± 4.87 | -1.1 ± 4.99 | 3.1 ± 5.37 |
| DBP,Day 3,n=74,75,16,75,75,16 | 3.2 ± 6.83 | 2.7 ± 5.95 | 1.3 ± 5.19 | 1.7 ± 5.74 | 1.2 ± 6.09 | 3.4 ± 5.76 |
| DBP,Day 4,n=73,75,16,75,75,16 | 7.4 ± 6.47 | 5.4 ± 6.64 | 6.1 ± 4.22 | 4.9 ± 6.51 | 5.3 ± 6.11 | 8.3 ± 6.94 |
| SBP,4 hour,n=75,76,16,75,75,16 | 1.5 ± 6.12 | 0.6 ± 5.94 | -0.8 ± 5.49 | 0.0 ± 5.04 | 0.5 ± 7.21 | 1.0 ± 7.28 |
| SBP,Day 2,n=74,75,16,75,75,16 | -0.5 ± 6.88 | -1.4 ± 6.05 | 0.4 ± 3.91 | -1.5 ± 5.10 | -1.7 ± 7.12 | 1.9 ± 8.06 |
| SBP,Day 3,n=74,75,16,75,75,16 | 4.0 ± 6.67 | 2.7 ± 6.15 | 2.9 ± 4.84 | 1.9 ± 7.28 | 1.6 ± 7.50 | 2.3 ± 7.73 |
| SBP,Day 4,n=73,75,16,75,75,16 | 8.2 ± 8.09 | 7.5 ± 8.43 | 7.0 ± 5.80 | 7.0 ± 8.86 | 7.2 ± 8.72 | 7.6 ± 8.42 |
HR was measured in the supine or semi-supine position after 5 minutes rest. The Baseline value was considered to be the participant's last available assessment prior to time of the first dose. Change from Baseline was defined as post dose visit value minus Baseline value. Data for HR for Part 1 and 2 is presented.
| Beats per minute | Part 1- A: DTG 50 mg + EPIVIR 300 mg | Part 1- B: DTG 50 mg/ 3TC 300 mg Monolayer FDC | Part 1-Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed | Part 2- A: DTG 50 mg + EPIVIR 300 mg | Part 2-C: DTG 50 mg and 3TC 300 mg Bilayer FDC | Part 2-Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed |
|---|---|---|---|---|---|---|
| 4 hour,n=75,76,16,75,75,16 | 0.6 ± 5.49 | 0.4 ± 4.25 | 4.9 ± 3.84 | 0.1 ± 5.25 | -0.3 ± 5.43 | 3.0 ± 3.22 |
| Day 2,n=74,75,16,75,75,16 | 2.2 ± 5.53 | 1.9 ± 4.60 | 2.9 ± 4.17 | 1.6 ± 5.48 | 0.6 ± 5.74 | 1.6 ± 5.44 |
| Day 3,n=74,75,16,75,75,16 | 5.1 ± 8.15 | 6.0 ± 6.35 | 5.8 ± 6.80 | 5.3 ± 7.23 | 3.8 ± 7.13 | 7.7 ± 10.42 |
| Day 4,n=73,75,16,75,75,16 | 7.5 ± 9.28 | 8.9 ± 7.68 | 9.6 ± 9.15 | 8.9 ± 8.31 | 6.1 ± 8.39 | 9.5 ± 10.10 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinaemia were categorized as SAE. Participants having any AE or SAE are presented.
| Participants | Part 1- A: DTG 50 mg + EPIVIR 300 mg | Part 1- B: DTG 50 mg/ 3TC 300 mg Monolayer FDC | Part 1-Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed | Part 2- A: DTG 50 mg + EPIVIR 300 mg | Part 2-C: DTG 50 mg and 3TC 300 mg Bilayer FDC | Part 2-Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed |
|---|---|---|---|---|---|---|
| AEs | 14 | 18 | 1 | 15 | 12 | 1 |
| SAEs | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over AEs and SAEs were collected from the start of study treatment until the follow-up contact (Up to 11 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1- A: DTG 50 mg + EPIVIR 300 mg | 0/75 (0%) | 0/75 (0%) | 2/75 (2.7%) |
| Part 1- B: DTG 50 mg/ 3TC 300 mg Monolayer FDC | 0/76 (0%) | 0/76 (0%) | 5/76 (6.6%) |
| Part 1-Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed | 0/16 (0%) | 0/16 (0%) | 1/16 (6.3%) |
| Part 2- A: DTG 50 mg + EPIVIR 300 mg | 0/75 (0%) | 0/75 (0%) | 8/75 (10.7%) |
| Part 2-C: DTG 50 mg and 3TC 300 mg Bilayer FDC | 0/75 (0%) | 0/75 (0%) | 6/75 (8%) |
| Part 2-Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed | 0/16 (0%) | 0/16 (0%) | 1/16 (6.3%) |
| Event | Part 1- A: DTG 50 mg + EPIVIR 300 mg | Part 1- B: DTG 50 mg/ 3TC 300 mg Monolayer FDC | Part 1-Bfed: DTG 50 mg and 3TC 300 mg Monolayer FDC Fed | Part 2- A: DTG 50 mg + EPIVIR 300 mg | Part 2-C: DTG 50 mg and 3TC 300 mg Bilayer FDC | Part 2-Cfed: DTG 50 mg and 3TC 300 mg Bilayer FDC Fed |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 2/75 | 5/76 | 1/16 | 8/75 | 6/75 | 0/16 |
| ContusionInjury, poisoning and procedural complications | 0/75 | 0/76 | 0/16 | 0/75 | 0/75 | 1/16 |
| Skin abrasionInjury, poisoning and procedural complications | 0/75 | 0/76 | 0/16 | 0/75 | 0/75 | 1/16 |
Safety Population: All participants who enrolled in the study and received at least one dose of study drug.
| Age, Continuous(Years) | Part 1 | Part 2 | Total |
|---|---|---|---|
| Mean | 29.4 ± 9.37 | 31.6 ± 11.18 | 30.5 ± 10.33 |
| Sex: Female, Male(Participants) | Part 1 | Part 2 | Total |
|---|---|---|---|
| Female | 25 | 26 | 51 |
| Male | 53 | 50 | 103 |
| Race/Ethnicity, Customized(Participants) | Part 1 | Part 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 6 | 1 | 7 |
| Asian- Central/South Asian Heritage | 1 | 1 | 2 |
| Asian- East Asian Heritage | 0 | 1 | 1 |
| Asian- South East Asian Heritage | 1 | 0 | 1 |
| Black or African American | 20 | 23 | 43 |
| White-White/Caucasian/European Heritage | 50 | 50 | 100 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2017 to primary completion in Aug 2017, 4 months.
Results were first posted in Feb 2019, 1 year 6 months after primary completion.
Of 51 industry-sponsored phase 1 interventional studies under Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 13. This study's 4 months is below that.
Counting every sponsor, half of 78 studies reached it within 10 months; a quarter within 3 and three quarters within 20.
Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dolutegravir · Lamivudine